After Months Of Silence, Wockhardt Says It Has “Enough Business Bandwidth” To Ensure Payments Of FCCBs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Drug major Wockhardt indicated that it has "enough bandwidth" in its business model to ensure that all its balance payments will be made in the stipulated time, in response to PharmAsia News queries on market speculation about its forthcoming payment of foreign currency convertible bonds of nearly $110 million. The bonds are scheduled to come up for redemption in September later this year
You may also be interested in...
Wockhardt In Final Stages Of Talks To Sell German Operation To Lindo Pharm
MUMBAI - Financially troubled Indian drug maker Wockhardt is close to selling Esparma - its German operation - to Lindo Pharm, a privately held German company specializing in thyroid preparations and antibiotics
Wockhardt In Final Stages Of Talks To Sell German Operation To Lindo Pharm
MUMBAI - Financially troubled Indian drug maker Wockhardt is close to selling Esparma - its German operation - to Lindo Pharm, a privately held German company specializing in thyroid preparations and antibiotics
Buzz Of Bids By GSK, Sanofi And Merck Get Louder As Piramal, Wockhardt Decline Sell-Off Talks
MUMBAI - Despite repeated denials, market buzz is getting louder that India's Piramal Healthcare is engaged in preliminary negotiations with multinational drug companies like GlaxoSmithKline, Sanofi-Aventis and Merck for a potential sell off